Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase ...

The famous trees, and the festival associated with their blossoming each spring, is part of a tradition for the global ...

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug ...

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

In a press release, Merck KGaA CEO and chair of the executive board Belen Garijo said, “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck KGaA, ...

Led by Brett Casper, a senior principal at Blue Fin Group, his agenda revolved around outlining the evolving orthodoxies for commercialization of ORD, CGT, and precision medicine; commercialization ...

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping ...

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on ...

Results from the dual Phase III TRIUMpH trials demonstrated the statistical superiority of tegoprazan over lansoprazole in ...

CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare ...